Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CYTEK BIOSCIENCES, INC. reported revenue of $201M, up 0.5% year over year. Operating margin was -20.0% and net margin -33.0%, on a free-cash-flow margin of -4.4% with capital expenditure at 2.0% of revenue. Every figure is computed directly from CTKB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $201M | -20.0% | -33.0% |
| FY2024 | $200M | -10.2% | -3.0% |
| FY2023 | $193M | -14.4% | -6.3% |
| FY2022 | $164M | -1.1% | 1.5% |
| FY2021 | $128M | 7.2% | 2.4% |
How does CTKB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: TMO · NOC · MDT · SYK · MMM · DHR
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.